Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3968 - International prognostic scores (IPS-7, IPS-3 and IPS-3 new) for prediction of FFS and OS in cases with Hodgkin Lymphoma. Which is more practical and accurate?


09 Sep 2017


Poster display session




Semra Paydas


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


S. Paydas1, M. Dogan2, V. Ercolak3, G. Seydaoglu4

Author affiliations

  • 1 Medical Oncology, Cukurova University, 01330 - Adana/TR
  • 2 Medical Oncology, Ankara Numune Hospital, Ankara/TR
  • 3 Medical Oncology, Mersin Hospital, Mersin/TR
  • 4 Biostatistics, Cukurova University, Adana/TR


Abstract 3968


Hodgkin Lymphoma (HL) is one of the curable malignant diseases. International prognostic score7 (IPS-7) was a valuable scoring system predicting FFP and OS in cases with HL. A simpler prognostic score: IPS-3 has been proposed 2 years ago and in this scoring system age and stage were found to be significant for FFP and age, stage and hemoglobin were found to be significant for OS. Here we evaluated IPS-3 new system in cases with HL.


364 patients with HL treated by ABVD have been included in this study. Two thirds of the patients had nodular sclerosing type HL, 76 had mixed cellularity type. Median follow up was 71 months.


Seven clinical parameters on the basis of the IPS-7 determined to be associated with adverse clinical outcome were evaluated. The prognostic ability of seven IPS factors was evaluated for both FFP and OS. A new 3-factor prognostic score (IPS-3 new) was constructed utilizing factors that were significant in multivariate Cox models: age>45 years, stage IV disease and lymphocytopenia were found to be independent factors. Thus IPS-3-new was constructed utilizing these 3 factors that were significant in multivariate Cox models. Lymphocytopenia was used instead of hemoglobin


The IPS-3 new covering lymphocytopenia instead of anemia besides age and stage factors on risk prediction for FFS and OS may provide a more accurate and reliable framework for risk assessment for the patients with HL.IPS-3 new is important due to the predictive property of lymphocytopenia in HL in immunotherapy era.

Clinical trial identification

Legal entity responsible for the study

Semra Paydas et al




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.